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SOMMARIO 
L'obiettivo di questo studio è quello di valutare la prevalenza e l'incidenza di 
fratture osteoporotiche e di identificare i loro principali determinanti (malattia 
primaria, dosaggio glucocorticoidi, densità minerale ossea, fattori di rischio, 
trattamento specifico per osteoporosi indotta da steroidi)  in un'ampia coorte di 
pazienti consecutivi di età > 21 anni, in terapia cronica con glucocorticoidi (≥5 mg 
di prednisone -PN- equivalente), afferenti presso centri di reumatologia situati in 
tutta Italia. Lo studio è uno studio nazionale osservazionale, multicentrico, 
trasversale e longitudinale. 
Sono stati arruolati 553 pazienti affetti da Artrite Reumatoide, Polimialgia 
Reumatica e Malattie del Tessuto Connettivo e in trattamento cronico con 
glucocorticoidi.  
Lo studio GIOTTO potrebbe fornire importanti contributi nella pratica clinica, in 
particolare evidenziando e quantificando la prevalenza della osteoporosi indotta 
da glucocorticoidi (GIOP) e delle relative fratture nella real life, la frequenza dei 
principali fattori di rischio, e strategie di prevenzione sub-ottimale. 
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ABSTRACT 
Background: Osteoporosis and fractures are common and invalidating 
consequences of chronic glucorticoid (GCs) treatment. Reliable information 
regarding the epidemiology of GCs induced osteoporosis (GIOP) are coming 
exclusively from the placebo group of randomized clinical trials while 
observational studies are generally lacking data on the real prevalence of vertebral 
fractures, GC dose and primary diagnosis. 
Objectives: The objective of this study was to evaluate the prevalence and 
incidence of osteoporotic fractures and to identify their major determinants 
(primary disease, GCs dose, bone mineral density,risk factors, specific treatment 
for GIOP) in a large cohort of consecutive patients aged > 21 years, on chronic 
treatment with GC (≥5 mg prednisone –PN- equivalent), attending rheumatology 
centers located all over Italy. 
Methods:This is a national multicenter cross-sectional and longitudinal 
observational study (The Glucocorticoid Induced OsTeoporosis TOol, GIOTTO 
Study). 553 patients suffering from Rheumatoid Arthritis (RA), Polymyalgia 
Rheumatica (PMR) and Connective Tissue Diseases (CTDs) and in chronic 
treatment with GCs were enrolled.  
Results: Osteoporotic BMD values (T score < -2.5) were observed in 28%, 38% 
and 35% of the patients with CTDs, PMR or RA at the lumbar spine, and in 18%, 
29% and 26% at the femoral neck, respectively. Before GC treatment prevalent 
clinical fractures had been reported by 12%, 37% and 17% of patients with CTDs, 
PMR, and RA, respectively. New clinical fragility fractures during GC treatment 
was reported by 12%, 10% and 23% of CTDs, PMR and RA patients, 
respectively. Vertebral fractures were the prevailing type of fragility fracture. 
More than 30% of patients had recurrence of fracture. An average 
of 80% of patients were in supplementation with calcium and/or vitamin D during 
treatment with GCs. Respectively,64%, 80%, and 72% of the CTDs, PMR and 
RApatients were on pharmacological treatment for GIOP, almost exclusively with 
bisphosphonates. 
Conclusions: The GIOTTO study might provide relevant contributions in clinical 
practice, in particular by highlighting and quantifying in real life the prevalence of 
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GIOP and relative fractures, the frequency of the main risk factors, and the 
currently sub-optimal prevention. Moreover, these results emphasize the 
importance of the underlying rheumatic disease on the risk of GIOP associated 
fractures. 
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INTRODUCTION 
Glucocorticoid therapy (GCs) is frequently used in the treatment of rheumatic 
diseases, as Rheumatoid Arthritis (RA), Polymyalgia Rheumatica (PMR), and 
Connective Tissue Diseases (CTDs) such as Systemic Lupus Erythematosus 
(SLE) (1,2,3).  
 In RA the use of low-dose GCs has a well-defined effect on disease activity (4). 
In early RA, many evidences demonstrate that the treatment with conventional 
synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in association 
with GCs may induce high and persistent remission rates (5). This disease-
modifying effect of GCs is supported by different studies (5-12). These studies 
have demonstrated that GCs have an action in retarding the progression of erosive 
joint damage in early RA (prior to any joint damage) and a control of disease 
activity (5-12). The CAMERA II study, in which patients with RA and treated 
with 10 mg/day of prednisone, has demonstrated that in RA patients the co-
treatment with GCs has a role in the treat-to-target and tight control strategy (13).  
Many reviews have concluded that low dose of GCs (<7,5 mg/day) can represent 
a “bridging-therapy” while waiting for csDMARDs begin to have effect (8,13). 
This conclusion is recommended by EULAR in early RA in 2010 and then in 
2014 update (14-16). The 2012 update ACR recommendations treatment of RA 
concerned only about the use of conventional DMARDs and biological therapies, 
while did not recommend the use of GCs (17). In RA the combination therapy 
with GCs (at stable low dose of 7,5 mg/day) and traditional DMARDs frequently 
results in a suppression of inflammation, and allows a lasting clinical remission 
(5). 
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In the EULAR 2016 recommendations update, the term “low-dose” is deleted and 
replaced by “short-term”, leaving the choice about dose regimens and route of 
administration to the individual rheumatologist and patient (18). In addition, the 
Task Force underlines that GCs should be gradually reduced and ultimately 
stopped, usually within 3 months from treatment start and only exceptionally by 6 
months. Long-term use of GCs, especially at doses above 5 mg/day, should be 
avoided because of the many adverse effects (osteoporosis, 
hyperglycaemia/diabetes mellitus, cardiovascular diseases and infections). Strehl 
et Al., in their study have agreed that the risk of harm is low for the majority of 
patients at long-term dosages of ≤5 mg prednisone equivalent per day, whereas at 
dosages of >10 mg/day the risk of harm is elevated. At dosages between >5 and 
≤10 mg/day, patient-specific characteristics (protective and risk factors) determine 
the risk of harm. The level of harm of glucocorticoids depends on both dose and 
patient-specific parameters. General and glucocorticoid-associated risk factors and 
protective factors such as a healthy lifestyle should be taken into account when 
evaluating the actual and future risk (19). 
In the report of Chatzidionysiou et Al, a systematic literature review informig the 
2016 update of the recommendationd for the management of RA has been 
performed. The Authors conclude that addition of GCs to csDMARDs therapy 
may be beneficial, but the benefits should be balanced against the risk of toxicity. 
Under tight control conditions, methotrexate (MTX) monotherapy is not less 
effective than csDMARDs, but better tolerated (20). A small study by Menon et 
Al. has shown a greater combination of csDMARDs with intrarticular GCs than 
with csDMARDs alone in patients with RA with less than 2 years disease 
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duration, although this is an open label study with high bias risk (21). In the 
CareRA trial, early RA patients, without prognostic factors, have benefited from 
the addition of GCs (COBRA-slim) to MTX with no differences in safety 
observed (22). A non-inferiority trial has compared two different GCs strategies; 
the COBRA-light strategy (prednisolone at 30 mg/day, tapered to 7,5 mg/day in 9 
meeks) in combination with MTX; and the COBRA strategy, using prednisolone 
at 60 mg/day (tapered to 7,5 mg/day in 6 weeks) in combination with both MTX 
and sulfasalazine. The lower dose of GCs was efficacious in suppressing clinical 
disease activity and improving functional ability, but non-inferiority could not be 
claimed formally (23, 24). The degree of radiographic progressionis similar in the 
two groups (COBRA and COBRA-light). This study has high risk of bias too, and 
no comparison with application of conventional GCs was performed.  
In a double-blind RCT with patients with established RA, low-dose prednisone 
with modified release added to existing DMARD treatment in patients with active 
disease has a significant effect on disease activity and health-related quality of life 
compared with placebo (25). 
In their study, Shimizu et Al. have analyzed data from the Institute of 
Rheumatology, Rheumatoid Arthritis (IORRA) database, a large-scale, 
prospective cohort database of RA patients, with the goal of identifying changes 
in the proportions of biologic DMARDs (bDMARDs) users receiving MTX and 
glucocorticoids and changes in the doses of these medications over time in daily 
clinical practice (26). The proportion of patients using glucocorticoids decreased 
after the introduction of bDMARDs among users of all four bDMARDs 
(infliximab, etanercept, adalimuma, tocilizumab). Glucocorticoid doses also 
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decreased in allbDMARD groups, with no significant differences observed 
between groups. Several reports have focused on concomitant glucocorticoid use 
after initiation of bDMARDs (27,28,29). Notably, in the STREAM study, a 
steroid-sparing effect was observed as a benefit of Tocilizumab therapy (30). In 
the IORRA cohort, concomitant glucocorticoids were decreased and discontinued 
in 63.7% and 18.0% of baseline glucocorticoid users, respectively, suggesting that 
a higher proportion of patients attempted to decrease glucocorticoid use. 
However, few RA patients are able to discontinue glucocorticoid use, even after 
initiation of a bDMARD. Of the 21,672 RA patients registered in the U.S. 
National Data Bank, 35.5% used glucocorticoids at the time of the survey and 
65.5% had used them at some point in their lifetime (31). Even among patients 
who had achieved remission and patients with well-controlled disease activity, 
21% to 25% still used glucocorticoids. Likewise, the study of Shimizu et Al. 
revealed that 51.4% of patients continued to use glucocorticoids even though their 
disease activity was well-controlled after approximately 2 years of bDMARD 
treatment. The IORRA cohort study revealed that, in daily clinical practice, after 
the introduction of a bDMARD, MTX and glucocorticoid doses are commonly 
titrated down as disease activity decreases. These dose adjustments vary 
depending on which bDMARD is used. 
Several studies have explored the safety and the tolerabilityof glucocorticoids 
treatment in RA patients. In their editorial Buttgereit and Bijlsma support the 
chronic use of low-dose of GCs as a realistic option for some patients (32). The 
Authors recommend the use of low-dose of steroids both in early RA and in 
established RA. In support of this recommendation, a recent report of Roubille et 
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Al. has investigated, in a cohort of very early RA from a real-life setting 
monitored for 7 year, the association between exposure to GCs treatment and 
classical major safety events related to GCs (death, cardiovascular diseases, 
severe infections, fractures). The patients were stratified in two groups: with or 
without  GCs treatment. This 7-years analysis does not show any significant 
difference between patient with early RA with and without low-dose of  GCs 
treatment in terms of major safety events. Also in established RA, there are many 
patients obviously being more or less constantly treated with GCs. The German 
National Database of the Collaborative Arthritis describes that, in a total of 8084 
patients with RA, 48% received a mean dose of 5 mg prednisone equivalent per 
day, whereby 8,5% were treated with daily dosages < 5 mg, 37,7% with 5-7,5 mg 
and 2,1% with > 7,5 mg (33). So, during treatment of both early and established 
RA, the risk of adverse effects induced by conventional GCs can be minimised 
when following the established recommendations (34,35,36), and by considering 
each patient to be an individual person characterised by the presence or absence of 
certain risk factors and/or preventive measures. This will ultimately result in an 
adapted patient-specific therapy. Although these studies support the good safety 
profile of low-dose of GCs for early RA,  the GCs risk/benefit balance has little 
evidence base, with most recent data provided by observational studies. These 
studies provide the opportunity to explore the real-life tolerability profile of GCs, 
with doses and duration commonly used in daily practice, but often present bias 
such as confounding by indication (37). 
The GCs tolerability profile has been reported to depend both on the duration of 
exposure and dose (38). Indeed, in addition to a better tolerability profile of a low 
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dose than high-dose regimen (36), long-term use of low-dose GC has been 
associated with increased mortality as compared with shorter exposures 
(39).  Most notably, two recent studies have suggested a dose-dependent increase 
in mortality in RA (40,41); del Rincón et Al (40) revealed a daily threshold dose 
of 8 mg at which all-cause mortality increased with GCs dose, and in the German 
register Rheumatoid Arthritis oBservation of BIologic Therapy (RABBIT), use of 
GCs>5 mg/day was associated with increased mortality risk, independent of RA 
activity (41). Moreover, a 10-year follow-up study examined cardiovascular 
events and deaths in early patients with RA with no history of cardiovascular 
diseases who were included in a recent open-label randomised trial of low-dose 
prednisolone (7.5 mg/day) over the first 2 years of early RA Better Anti-
Rheumatic PharmacOTherapy (BARFOT+): low-dose prednisolone use was 
associated with increased incidence of cerebrovascular events and, although not 
significant, increased mortality (42).  Long-term follow-up of Computer Assisted 
Management in Early Rheumatoid Arthritis (CAMERA II) patients with early RA 
who received prednisone at 10 mg/day for at least 2 years revealed increased 
cardiovascular risk and, although not significant, increased mortality (43). 
Cardiovascular tolerance of GC remains controversial. In one meta-analysis of 
observational studies, GCs usage was associated with increased risk of all 
cardiovascular events, including myocardial infarction, heart failure and stroke 
(44). In another systematic literature review, low-dose GC (<10 mg/day) was 
associated with major cardiovascular events in four of six studies (45). GCs 
therapy has been associated with increased risk of severe infections (46, 47). One 
systematic review has noted the paucity of data on the association between low-
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dose GCs (<10 mg/day prednisone) and risk of infections (48). In one recent study 
evaluating patients with RA aged >65 years, the risk of serious infections was 
increased 30%, 46% or 100% with 5 mg prednisolone used continuously for the 
last 3 or 6 months or 3 years, respectively, as compared with no use (49). The 
increased risk of severe infections was also proportional to the cumulative dosage 
over 2–3 years. 
In their systematic review of guidelines for Glucocorticoids in RA (34), 
Palmowski et Al., have identified several potentially important clinical issues that 
are not addressed in any of the guidelines. The first of these issues is the timing 
and frequency of glucocorticoid administration. The interval between doses of 
DMARDs and biologic drugs used in thetreatment of RA is generally longer than 
that of glucocorticoid dosing, and they are overall less affected by endogenous 
hormonal regulatory circuits. In contrast, the effects of daily glucocorticoid 
therapy are highly influenced by their strong dependency on circadian rhythms. 
Thus, choosing the right administration schedule for glucocorticoids may have a 
considerable impact on both efficacy and safety, by minimizing adverse effects on 
the hypothalamic–pituitary–adrenal axisor by allowing equal symptom control 
with lower doses. The concept of considering timing of glucocorticoids 
administration in order to optimize the individual benefit/risk ratio is often 
referred to as “chronotherapy”. Although several studies have been reporting 
promising results concerning the potential benefit of chronotherapy for more than 
50 years (51,52,53) and various authors have emphasizedits importance 
(54,55,56). A rather recent approach to this issue is the use of modified/delayed 
release prednisone (57), which will be another important point to beconsidered in 
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future recommendations. A second topic scarcely considered by any guideline to 
date is the potential influence of patient-specific factors on the optimal treatment 
regimen. These patient-specific factors include comorbidities, co-medications, or 
other (relative) contraindications. None of the available guidelines comment 
specifically on treatment of elderly RA patients. Both incidence and prevalence of 
RA increase with age, and therefore elderly patients with RA represent a large 
segment of the RA population (58). In general, the elderly have more 
comorbidities than young people, and this is even truer for elderly patients with 
RA. Such patients receive multiple concomitant drugs, which may influence RA 
treatment choices (59,60). Also elderly patients with RA are more likely than 
younger patients to experience glucocorticoid-related adverse effects such as 
osteoporosis, diabetes mellitus, or hypertension.  
GCs represent the gold standard treatment in PMR. GCs reduce symptoms and 
suppress inflammation within a few weeks. GCs act by the inhibition of the 
circadian release of pro-inflammatory cytokines (such as IL-6), reduce the 
duration of morning stiffness (2). Although it is not accepted an universal regimen 
of daily doses of GCs in PMR, the EULAR/ACR 2015 recommendations for the 
management of PMR suggest to use the minimum effective GCs dose within a 
range of 12.5–25 mg prednisone (PN) equivalent daily as the initial treatment of 
PMR, and then at 10 mg for 4-8 weeks before being tapered by 1 mg every 4-8 
weeks provided no flares occur (61). In addition, the experts panel discourages 
conditionally the use of initial doses ≤7.5 mg/day and strongly recommends 
against the use of initial doses >30 mg/day. The panel recommends to consider the 
early introduction of methotrexate (MTX) in addition to GCs, particularly in 
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patients at a high risk for relapse. MTX may also be considered during follow-up 
of patients with a relapse, without significant response to GCs or experiencing 
GC-related adverse events (61). 
GCs are extensively used also for the treatment of CTDs, such as systemic lupus 
erythematosus (SLE)  and their complications or flares.  
GCs are used in the treatment of acute SLE as well as in the maintenance of 
remission and are often continued long-term. The most commonly used GCs in 
the treatment of SLE are prednisone and methylprednisolone; other GCs such as 
triamcinolone and dexamethasone are used less frequently (62). Although GCs 
have been administered in divided doses, particularly at medium to high doses, 
single morning administration appears advisable to minimise both adverse effects 
and suppression of the pituitary axis (63). Therapeutic protocols of GCs for SLE 
range from low (0.1–0.2 mg/kg/day), to medium (0.2–0.5 mg/kg/day), to high 
doses (0.5–1 gm/kg/day) and intravenous pulses (doses ranging from 250 to 1000 
mg/daily for 3 consecutive days) and are used for induction and maintenance of 
remission (62). Low-dose GCs (0.1–0.2 mg/kg/day) are generally used as 
maintenance treatment, often even in the absence of active disease. Low to 
medium (0.2–0.5 mg/kg/day), doses are also used in the treatment of mild disease 
activity, particularly cutaneous, muscoloskeletal, haematological and 
constitutional manifestations.  
In their review Mosca et Al., conclude that, although many drugs have been 
introduced in the treatment of SLE, GCs still represent a cornerstone in the 
treatment of SLE in all its clinical aspects and different levels of severity (64). 
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As mentioned above, the use of GCs is associated to the occurrence of side 
effects, including hypertension, diabetes mellitus, cataract (65,66). The more 
common side effects of GCs in low (<7.5 mg/day) to moderate doses (7.5-30 
mg/day prednisolone equivalent) are osteoporosis, diabetes, cataracts, thinning of 
the skin, weight gain and fat redistribution. At higher doses, infections, myopathy, 
psychological disturbances and osteonecrosis are seen (67,68,69). 
One of the principal complications of long-term GCs use is an important alteration 
of bone metabolism. The bone loss associated with GCs generally involves 
trabecular and cortical bone, with increased bone resorption but mainly decreased 
bone formation (70). The bone loss is likely to proceed more rapidly and involves 
first the trabecular compartment because trabecular bone has more available 
surface upon which the cycle of resorption and formation occurs. Rapid bone loss 
is most marked on endocortical surfaces (71). Doses of GCs >5 mg PN equivalent 
per day are associated with bone loss due to reduced bone formation. Doses of <5 
mg per day may be skeletal sparing, but it is unpredictable if doses <5 mg are 
efficacious (72). Indeed GCs play a dual role: they induce bone loss, but on the 
other hand they suppress systemic inflammation with a subsequent beneficial 
effect on bone mass (3). Fracture risk is positively related to daily dose and 
increases during the first 6 months of therapy (73), and the relative risk of 
fractures for patients in GCs therapy is higher for forearm, hip and vertebral sites 
(73). Some confounding factors such as activity of the disease, age of the patient, 
sex, baseline BMD previous fracture history, may influence the rate of bone loss 
(36). The effects of GCs on fracture risk as well as being dose-related, also 
depend on the duration of the therapy (74).  
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It is well known that GCs determine a decrease in osteoblastogenesis and interfere 
with osteoblastic differentiation and maturation (75). In addition, GCs inhibit the 
Wnt/β-catenin pathway, which is critical for the differentiation of mesenchimal 
cells toward mature osteoblasts, with a consequent reduction of osteoblastogenesis 
(75,76). Also the osteocytes are influenced by the action of GCs. GCs induce the 
apoptosis of osteocytes by the activation of Caspase 3 (76). Recent studies 
demonstrate that treatment with GCs is related to an increased autophagy of 
osteocytes (77,78). In the GCs-induced osteoporosis the osteocyte-lacunar-
canalicular network is altered (75); this change together with the osteocyte 
apoptosis may explain the alteration of biomechanical properties in the bone (76). 
The third type of cells influenced by GCs are osteoclasts. GCs determine an 
increase in osteoclastogenesis and a prolongation of osteoclasts lifespan (76) by 
the increased expression of the macrophage colony stimulating factor (M-CSF) 
and the receptor activator of NF-ĸβ ligand (RANK-L) (75). The canonical Wnt 
system has extracellular inhibitors: Dickkopfs (DKK1) and Sclerostin. DKK1 
determines an inhibition of osteoblastogenesis (79). Furthermore, the lack of 
stimulus of β-catenin on the OPG production by osteoblasts determines the 
imbalance of RANKL/OPG in favor of RANK-L and therefore of bone resorption. 
In conclusion, DKK1 inhibits bone formation while induces bone resorption 
(80,81). 
Sclerostin is expressed by osteocytes with an important role in regulating bone 
formation by osteoblasts. Sclerostin is a monomeric glycoprotein, which 
antagonizes the canonical Wnt pathway in osteoblasts (82) by the inhibition of 
differentiation, activity and survival of osteoblasts (83). Recent studies in cultures 
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of osteoblasts treated with dexamethasone have shown an alteration of 
osteoblastic differentiation through the inhibition of the canonical Wnt/β-catenin 
pathway (84,85,86,87), and an overespession of Wnt-antagonists (86,88,89).  
While several in vivo and in rodents studies about the effect of GCs on Wnt 
signaling are widely available, studies in humans are poor, and results are 
discordant and controverse, probably because conducted with different doses and 
underlying diseases.  
Reliable information regarding the epidemiology of GC induced osteoporosis 
(GIOP) are coming exclusively from the placebo group of randomized clinical 
trials while observational studies are generally lacking data on the real prevalence 
of vertebral fractures, GC dose and primary diagnosis. 
In the 2017 ACR recommendation fot the prevention and treatment of GIOP (90), 
Buckey et Al., outline the treatment recommendation for GIOP. The Authors 
consider it is crucial to identify those patients taking GCs for whom the benefits 
of preventive therapy sufficiently outweigh potential harms, since GCs treatment 
is a potentially reversible risk factor for GIOP. Firstly, in all adults and children, 
an initial clinical fracture risk assessment should be performed as soon as 
possible, but at least within 6 months of the initiation of long-term GCs treatment. 
For all patients receiving GCs treatment, optimizing calcium intake and vitamin D 
intake, as well as a lifestyle modifications, are recommended. Oral 
bisphosphonates are recommended as the preferred first-line therapy in most 
clinical situations given their antifracture benefit, safety, and low cost, unless 
there are contraindications, intolerance, or concerns about patient adherence to 
treatment 
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The main objective of this multicenter study was to evaluate, with a transversal 
and longitudinal approach, in the real life, the prevalence and incidence of 
osteoporotic fractures and to identify their major determinants in a sample of 
patients with different rheumatic diseases in chronic treatment with 
GCs.Secondary objectives were to quantify the prevalence of the major risk 
factors for osteoporotic fracture: age, underlying disease, sex, bone mineral 
density (BMD), dietary intake of calcium, specific anti-osteoporotic therapy, 
estimate of vitamin D, physical activity, smoking, alcohol, family history, 
comorbidity and falls. 
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METHODS 
This is a national multicenter cross-sectional and longitudinal observational study 
(The Glucocorticoid Induced OsTeoporosis TOol, GIOTTO Study). 553 patients 
suffering from RA, PMR and CTDs and in chronic treatment with GCs were 
enrolled in the italian rheumatologic centers of Verona, Vercelli, Mantova, Pavia, 
Modena, Bologna, Firenze, Pisa, Siena, Ancona, Roma, Napoli, Foggia, Lecce, 
Reggio Calabria, Catania, and Cagliari (fig. 1). 
The study was purely observational so no additional treatments or tests to that 
normally applied in these patients, were provided or requested. 
Each center has enrolled patients presenting consecutively in their outpatients 
clinics and within the following inclusion criteria: 
• for the “transversal phase”: women or men age > 21 years and receiving 
GCs at least from one year at a dose of at least 5 mg/day of PN or 
equivalent 
• for the “longitudinal phase”: patients in therapy with GCs (at least 5 
mg/day) for less than three months and in which was expected a therapy 
with GCs for at least one year at a dosage of at least 5 mg/day of PN or 
equivalent. 
All subjects with at least one of the following characteristics were excluded from 
the study: a diagnosis of metabolic bone diseases or other forms of secondary 
osteoporosis (uncontrolled hyperthyroidism, M. Cushing, malabsorption 
syndrome, primary hyperparathyroidism), severe renal insufficiency (serum 
creatinine> 2 mg/dl), severe liver failure. Patients on aromatase inhibitors, 
androgen deprivation therapy and heparin are also excluded (fig. 2). 
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Additional diagnostic tests (instrumental or biochemical) deemed appropriate by 
the investigator for the clinical practice were provided. The prevalence or 
incidence of fractures are referred to so-called clinical fractures (but also to any 
vertebral fractures detected incidentally by radiographic investigation of the 
column or the DXA investigation of the spine). 
The data collection cards (CRF) used collected information about the medical 
history, clinical, diagnostic and therapeutic data, and in particular: demographics; 
physiological and pathological history; assessment of the state of the rheumatic 
disease and concomitant Health Assessment Questionnaire; previous drug therapy; 
previous and ongoing glucocorticoid therapy; specific anamnesis for osteoporosis: 
date of first diagnosis; date of  first atraumatic fracture; pain symptoms; previous 
fractures (before or after the start of therapy GC)/fractures at the baseline visit; 
outcome laboratory examinations; previous/ongoing drug therapy for 
osteoporosis; risk factors; assessment of the quality of life (EQ-5D); simplified 
questionnaire of calcium and vitamin D intake and physical activity (fig. 
3,4,5,6,7). 
The study was approved by the Ethics Committee and by the local coordinator. All 
patients provided written informed consent. 
Descriptive statistics analysis included: sample size, mean, standard deviation, 
median and range for continuous variables; absolute and relative frequency 
distributions for categorical variables. 
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RESULTS 
A total of 553 patients with RA, CTDs (mainly SLE = 93%) or PMR in chronic 
treatment with GCs have been recruited. Table 1 shows the main clinical features 
of the patients depending on the disease. 
The prevalence of the main risk factors for osteoporosis and fracture, according to 
the disease that requested GCs chronic therapy, is shown in Table 2. 
The prevalence of osteoporosis according to DXA (T-score <-2.5)  was at the 
spine in 28%, 38% and 35% of patients with CTDs, PMR or RA; instead at the 
femur it was respectively 18%, 29% and 26% (Fig. 8). 
A prevalence of anamnestic clinical fractures has been found in 12%, 37% and 
17% of patients suffering from respectively CTDs, PMR, or RA before any 
treatment with GC (Fig. 9A). 
During treatment with GC new clinical fragility fractures were reported in 12%, 
10% and 23% in patients suffering from CTDs, PMR and RA, respectively (Fig. 
9B). 
The prevailing type of fragility fracture has been the vertebral one, in particular 
multiple vertebral fractures in patients suffering from PMR (Fig. 10A). 
More than 30% of patients had recurrence of fracture. A second relapse 
of a fragility fracture was found in 20% of patients with CTDs and 10% of those 
with RA (Fig. 10B). 
In addition, considering only calcium and/or vitamin D, an average 
of 80% of patients were in supplementation during treatment with GCs; only few 
of them were already on treatment before the beginning of the GCs treatment (Fig. 
11A).   
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64% of patients with CTDs, 80% of patients with PMR and 72% of patients with 
RA, were treated with specific drugs for the prevention or treatment of GIOP, and 
in particular with anti-resorptive drugs (alendronate or risedronate) (Fig. 11B). 
The patients included in the prospective longitudinal phase of the study, which 
met the inclusion and exclusion criteria, were 83. Their assessment did not show 
any significant results in addition to those shown by the retrospective longitudinal 
analysis of 553 cases. 
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DISCUSSION 
The main aim of this multicenter study was to evaluate the prevalence and the 
incidence of osteoporotic fractures in a cohort of patients with different rheumatic 
diseases and in therapy with chronic GCs.  
In this study we have observed that the prevalence of osteoporosis in RA patients 
according to DXA, in terms of T-score < - 2,5, was at the spine of 35%, while at 
the femur was 26%. In previous studies the frequency of generalized osteoporosis 
in patients with RA ranges from 12.3 to 38.9 % in the lumbar spine and from 6.3 
to 36.3 % in the hip (91-93). The KORONA database showed that the frequency 
of osteoporosis was 46.8 % (94). This frequency was higher in comparison to 
some other studies, which reported a prevalence of 22–24 % (95,96). In a large 
Italian multicenter cross-sectional study that included 925 female RA patients the 
Authors described that the frequency of osteoporosis in the whole sample 
was 28.8% at lumbar spine and 36.2% at femoral neck (92).  
In our study the prevalence of osteoporosis in patients with CTDs (mainly SLE) 
was at the spine of 28% and 18% at the hip. Recently, Carli et Al. observed that 
more than 50% of SLE patients chronically treated with GCs had a reduced BMD 
and 28% had osteoporosis (97). In previous studies the prevalence of osteoporosis 
ranged from 1,4 to 68% of patients with SLE (98,99). Two recent studies have 
demonstrated that bone loss occurs mainly in SLE patients treated at least with 7,5 
mg/day prednisone, while treatment with lower doses of prednisone is not 
associated with bone loss (100,101).  
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The frequency of osteoporosis in patients with PMR in previous studies ranges 
between 14.9 and 85%. In our experience, in these elderly patients osteoporosis 
was generally found in 38% at the spine and 29% at the hip. 
Risk of fracture in patients who received long-term GC is about 33–50%, which 
depends on daily and cumulative dose (102). This diversity can be explained by 
the use of different age groups in the study populations, the menopausal status of 
the participants, and the use of GCs. In addition, we observed that the prevalence 
of anamnestic clinical fractures before any GCs treatment was 12% in patients 
with CTDs, 37% in patients with PMR and 17% in patients with RA. This finding 
may be explained by the role of underlying inflammation. In general population, 
even small elevations of C reactive protein within the normal range increase non-
traumatic fracture risk (103). In some studies, variations within the low levels of 
inflammatory markers and cytokines predict bone loss and elevated inflammatory 
markers are prognostic for fractures (104,105). There is a strong biological 
rationale for these observations. Osteoclastogenesis is under the control of 
RANK-ligand, which is mainly produced by osteocytes in normal bone 
remodelling, but also by lymphocytes and fibroblasts in other situations (106) and 
inflammation. Osteoclastogenesis can be enhanced by many cytokines: interleukin 
(IL) IL-6, IL-23, Tumor necrosis factor α (TNF-α). TNF-α transgenic mice are 
models of osteoporosis with dramatic decrease in bone mass and deterioration of 
bone microarchitecture.  
These findings show that inflammation has a deleterious effect on bone 
remodelling, inducing an increased resorption and a decreased formation, before 
any effect of GCs themselves. 
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As mentioned in the introduction, the Wnt pathway is critical for bone formation 
(107). Several studies have reported a rise in Wnt inhibitors (sclerostin and 
DKK1) expression in rodents and cell culture systems following GCs treatment 
(81,88,108,109). The evidence for a substantial link in human patients has been 
discordant with decreased serum sclerostin at one week in GCs patients (110) and 
increased serum sclerostin at later time points (111), with a consequence of 
inflammation-related decrease in bone formation (112). Similar disparities are 
seen with sclerostin and disease states: increased levels are reported in Cushing’s 
syndrome patients, (113) whereas cases of chronic hypercortisolism presented 
with decreased sclerostin (114).  
Moreover, alterations in other Wnt inhibitors, such as DKK1, might be involved 
in inflammation-related bone loss (115). 
The effects of GCs treatment on serum levels of DKK1 have been studied in many 
diseases with discordant results. Brabnikova Maresova et al. have shown 
increased values of DKK1 during short-term GCs treatment (110). On the 
contrary, long-term studies showed a decrease of serum levels of DKK1 (111). 
The reasons for these controversial results are unknown, probably factors as GCs 
dose and duration treatment, and any underlying diseases may play a role (85). 
The clinical significance of a reduction of DKK1 might be relevant. Gifre et al. 
have speculated that the osteocytes and/or the osteoblasts may attenuate the effect 
of GCs on the cell by lowering the secretion of DKK1, as a protective mechanism 
against cell death (111). In this way, the modulation of DKK1 signaling by GCs 
treatment limits both the onset of osteoblasts apoptosis than the differentiation of 
the adipocytes, and the bone mass loss (88).  
27 
 
In their study, Beier et Al. explored a mechanism involving induction of sclerostin 
as a facilitator of the negative effects of GCs on bone quality (116). The Authors 
concluded that bone loss associated with steroid-induced osteoporosis is a 
consequence of sclerostin-mediated restriction of Wnt signaling, which may 
mechanistically facilitate glucocorticoid toxicity in bone. 
Also autoimmunity might have a role in bone remodelling. For example, in RA 
the adaptive immune system produces antibodies against rheumatoid factor (RF) 
and/or against cyclic citrullinated peptides (antibodies to citrullinated protein 
antigens or ACPA). The plasma levels of ACPA are an index of disease activity 
and joint damage (117). A recent study has shown that ACPA can stimulate 
osteoclast differentiation, and that in patients with RA that are ACPA-positive 
there is a more frequent evidence of bone loss and thinning of cortical thickness 
than patient with RA and APCA-negative (118). Recently, a significant 
correlation has been observed between osteoporosis-RA related and risk of 
erosions (119,120).  
The incidence of new fragility fractures during GCs treatment in our cohort of 
patients was 12% in CTDs, 10% in PMR, and 23% in RA. The prevailing type of 
fractures was the vertebral one, in particular multiple vertebral fractures observed 
especially in patients with PMR. It is known that the risk of fractures is increased 
by twofold in patients with GCs, and the risk of vertebral fractures is even higher. 
In a study comparing 244.235 oral GCs users and 244.235 controls, the risk of hip 
fracture was 1.6, and the risk of vertebral fracture was 2.6; many studies have 
confirmed these numbers (73,121,122). The global prevalence of fractures in 
patients receiving long-term GCs has been reported to be 30–50%. In 551 patients 
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receiving long-term GCs, the prevalence of vertebral fractures was 37%, with 
14% of patients having 2 or more asymptomatic vertebral fractures; 48% of 
patients aged ≥70 years and 30% of those aged <60 years had at least one 
vertebral fracture (123). The increase in fracture risk is immediate, as early as 3 
months after the initiation of therapy and reverses sharply after discontinuation of 
GCs (73). This can be related to the added effects of GCs on bone remodelling 
previously uncoupled by the inflammation itself, and the dramatic effect on bone 
strength through induced apoptosis of osteocytes. Data also suggest a rapid 
increase in rate of falls after start of oral GCs (73). In epidemiological studies, the 
increased risk of fractures is observed even at low doses of prednisone, that is, 
2.5–5 mg per day. The appropriate care of patients receiving such low doses is not 
well defined. There is a dose-dependent increase in fracture incidence. 
Interestingly, the fracture risk is related to the current daily dose, more than to the 
cumulative dose (124): this may be related to the difficulty of an accurate 
calculation of this cumulative dose. 
Secondary objectives of this study were to quantify the prevalence of the principal 
risk factors for osteoporotic fractures. The prevalence of comorbidities was very 
high, especially in PMR. No physical activity was found in about 40% of the 
patients, independently by the rheumatic disease, and the prevalence of falls was 
high, in particular in RA and PMR (about 20%). Immobilization due to pain from 
inflamed joints and impairment of physical activity are known key factors related 
to low BMD and are common in patients suffering from rheumatic diseases (125). 
The risk of falls may be higher in RA patients because of lower limb joint disease 
and muscle weakness (due to GCs therapy and disuse) (126). An increased fall 
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risk in 89% of the RA patients was found (127). Potential interventions to reduce 
falling in this kind of patients, include control of disease activity, rehabilitation or 
exercise therapy, balance training, occupational therapy, home assessment and 
treatment of vitamin D deficiency. A study of Bearne et al. suggested that a “brief 
rehabilitation” can improve the quadriceps sensorimotor function (128).   
In addition, in our patients we found high prevalence of low sunlight exposure and 
low calcium intake. Vitamin D deficiency is common in patients with rheumatic 
disease, and associated with disease activity (129-131). We evaluated also the 
regular intake of calcium and vitamin D supplements before and during therapy 
with GCs. We observed that only a few patients were on supplementation before 
starting GCs therapy, while about 80% of patients taking calcium or vitamin D 
supplements during GCs therapy, as recommended (132). 
In our study prevention or treatment of GIOP with specific drugs for osteoporosis 
appear sub-optimal, and generally restricted to anti-resorptive approach with 
bisphosphonates (133), despite it is well known that inhibition of bone formation 
and increased apoptosis of osteocytes play a consistent and crucial role in the 
pathogenesis, while changes in bone resorption during GCs use are variable. 
Although it has been shown that bisphosphonates reduce vertebral fractures 
during the first 2 years of GC treatment, there are no data on long-term use, and, 
of some concerns in GIOP, bisphosphonates reduce bone turnover, including bone 
formation, which is already downregulated by GCs. Effectively, the use of the 
anabolic agent teriparatide was found more effective in reducing vertebral 
fractures than alendronate (134). 
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CONCLUSIONS 
In conclusion, the GIOTTO study might provide relevant contributions in clinical 
practice, in particular by highlighting and quantifying in real life the prevalence of 
GIOP and relative fractures, the frequency of the main risk factors, and the 
currently sub-optimal prevention. Moreover, these results emphasize the 
importance of the underlying rheumatic disease on the risk of GIOP associated 
fractures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
REFERENCES 
 
1. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, 
Badsha H, Peets T, Baranauskaite A, Geher P, Ujfalussy I, Skopouli FN, 
Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, 
Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, 
Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone 
D, Rexhepi S, Yazici Y, Pincus T. Women, men, and rheumatoid arthritis: 
analyses of disease activity, disease characteristics, and treatments in the QUEST-
RA study. Arthritis Res Ther 2009;11:R7;  
2. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X. 
Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 
2009;169: 1839-50; 
3. Bultink IE, Lems WF. Systemic lupus erythematosus and fractures.RMD 
Open. 2015;1(Suppl 1):e000069; 
4. Caporali R, Todoerti M, Sakellariou G, Montecucco C. Glucocorticoids in 
rheumatoid arthritis. Drugs 2013;73:31-43; 
5. Kirwan JR. The effect of glucocorticoids on joint detruction in rheumatoid 
arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study 
Group. N Eng J Med 1995;333:142-6; 
6. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van 
Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink 
HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S. Randomised 
comparison of combined step-down prednisolone, methotrexate and 
sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 
1997;350:309–18; 
7. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-
dose prednisone therapy for patients with early active rheumatoid arthritis: 
clinical efficacy, diseasemodifying properties, and side effects: a randomized, 
doubleblind, placebo-controlled clinical trial. Ann Intern Med 2002;136(1):1–12; 
8. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early 
rheumatoid arthritis retards radiographic progression over two years: a 
multicenter, double-blind, placebocontrolled trial. Arthritis Rheum 
2005;52(11):3371–80; 
9. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I. 
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic 
32 
 
drug in patients with early active rheumatoid arthritis reduces joint destruction 
and increases the remission rate: a two-year randomized trial. Arthritis Rheum 
2005;52(11):3360–70; 
10. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on 
radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 
2007;(1):CD006356; 
11. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, 
Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallee 
C, de Beus WM, de Sonnaville PB, Ewals JA, Breedveld FC, Dijkmans BA. 
Comparison of treatment strategies in early rheumatoid arthritis: a randomized 
trial. Ann Intern Med 2007;146(6):406–15; 
12. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Scott DL. 
Factorial randomised controlled trial of glucocorticoids and combination disease 
modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008;67(5):656–
63; 
13. Jabobs JWG. The CAMERA (Computer- Assisted Management in Early 
Rheumatoid Arthritis) studies. Clin Exp Rheumatol 2012;30(Suppl. 73):S39-43; 
14. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, 
Landewé R. Current evidence for the management of rheumatoid arthritis with 
glucocorticoids: a systematic literature review informing the EULAR 
recommendations for the management of rheumatoid arthritis.  2010;69(6):1010-
4; 
15. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester 
G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-
Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola 
E, Montecucco C, Schoels M, van der Heijde D; T2T Expert Committee. 
Treating rheumatoid arthritis to target: recommendations of an international task 
force.  2010;69(4):631-7; 
16. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados 
M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit 
M,Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe 
B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette 
X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott 
DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for 
the management of rheumatoid arthritis with synthetic and biological disease-
33 
 
modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-
509; 
17. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland 
LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW,Paulus 
HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King 
CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain 
A,Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 
update of the 2008 American College of Rheumatology recommendations for the 
use of disease-modifying antirheumatic drugs and biologic agents in the 
treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625-
39; 
18. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados 
M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer 
M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo 
M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec 
L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas 
M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór 
G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi 
T, Westhovens R, de Wit M, van der Heijde D. EULAR recommendations for the 
management of rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 
Jun;76(6):960-977; 
19. Cindy Strehl, Johannes W J Bijlsma, Maarten de Wit, Maarten Boers, Nele 
Caeyers, Maurizio Cutolo, Bhaskar Dasgupta, William G Dixon, Rinie Geenen, 
Tom W J Huizinga, Alison Kent, Annette Ladefoged de Thurah, Joachim 
Listing, Xavier Mariette, David W Ray, Hans U Scherer, Raphaèle Seror, 
Cornelia M Spies, Simon Tarp, Dieter Wiek, Kevin L Winthrop, Frank 
Buttgereit. Defining conditions where long-term glucocorticoid treatment has an 
acceptably low level of harm to facilitate implementation of existing 
recommendations: viewpoints from an EULAR task force. Ann Rheum 
Dis2016;75:952–7; 
20. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, 
Dougados M, Bijlsma J, Burmester G, Scholte M, van Vollenhoven R, Landewé 
R. Efficacy of glucocorticoids, conventional and targeted synthetic disease-
modifying antirheumatic drugs: a systematic literature review informing the 2016 
34 
 
update of the EULAR recommendations for the management of rheumatoid 
arthritis.Ann Rheum Dis. 2017 Jun;76(6):1102-1107; 
21. Menon N, Kothari SY, Gogna A, et al. Comparison of intra-articular 
glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid 
arthritis. J Assoc Physicians India 2014;62:673–6; 
22. Verschueren P, De Cock D, Corluy L, et al. Patients lacking classical poor 
prognostic markers might also benefit from a step-down glucocorticoid bridging 
scheme in early rheumatoid arthritis: week 16 results from the randomized 
multicenter CareRA trial. Arthritis Res Ther 2015;17:97; 
23. den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated 
combination strategy (‘COBRA-light’) compared to the original COBRA 
strategy: clinical results after 26 weeks. Ann Rheum Dis 2014;73:1071–8; 
24. ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment 
regimens, including prednisolone, are effective in treating patients with early 
rheumatoid arthritis regardless of additional etanercept: 1-year results of the 
COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum 
Dis 2015;74:1233–40; 
25. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for 
rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum 
Dis 2013;72:204–10; 
26. Shimizu Y, Tanaka E, Inoue E, Shidara K, Sugimoto N, Seto Y, Nakajima A, 
Momohara S, Taniguchi A, Yamanaka H. Reduction of methotrexate and 
glucocorticoids use after the introduction of biological disease-modifying anti-
rheumatic drugs in patients with rheumatoid arthritis in daily practice based on 
the IORRA cohort.Mod Rheumatol. 2017 Sep 14:1-7; 
27. Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumour 
necrosis factoralpha inhibitors in rheumatoid arthritis in real life practice. Clin 
Exp Rheumatol. 2009 Sep-Oct;27(5):807-13; 
28. Nilsson AC, Christensen AF, Junker P, Lindegaard HM.Tumour necrosis factor-α 
inhibitors are glucocorticoid-sparing in rheumatoid arthritis. Dan Med Bull. 2011 
Apr;58(4):A4257; 
29. Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, 
Gaudin P, Jorgensen C, Prades BP, Wendling D, Maillefert JF. Tocilizumab 
induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. 
Rheumatology (Oxford). 2015 Apr;54(4):672-7; 
35 
 
30. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-
term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal 
antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM 
study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum 
Dis. 2009;10:1580-4; 
31. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid 
arthritis:prevalence, predictors, correlates, and outcomes. J Rheumatol. 
2007;4:696-705; 
32. Buttgereit F, Bijlsma JWGlucocorticoids in rheumatoid arthritis: the picture is 
shaping up. Ann Rheum Dis. 2017 Nov;76(11):1785-1787; 
33. Albrecht K, Huscher D, Eidner T, et al. Medical treatment of rheumatoid arthritis 
in 2014 : current data from the german collaborative arthritis centers. Z 
Rheumatol 2017;76:50–7; 
34. Palmowski Y, Buttgereit T, Dejaco C, Bijlsma JW, Matteson EL, Voshaar 
M, Boers M, Buttgereit F. "Official View" on Glucocorticoids in Rheumatoid 
Arthritis: A Systematic Review of International Guidelines and Consensus 
Statements.Arthritis Care Res (Hoboken). 2017 Aug;69(8):1134-1141; 
35. van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-
dose glucocorticoid therapy: eular recommendations for clinical trials and daily 
practice. Ann Rheum Dis 2010;69:1913–9; 
36. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid 
treatment in rheumatoid arthritis: published evidence and prospective trial 
data. Ann Rheum Dis 2006;65:285–93; 
37. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term 
glucocorticoid treatment has an acceptably low level of harm to facilitate 
implementation of existing recommendations: viewpoints from an EULAR task 
force. Ann Rheum Dis2016;75:952–7; 
38. Ethgen O, de Lemos Esteves F, Bruyere O, et al. What do we know about the 
safety of corticosteroids in rheumatoid arthritis? Curr Med Res 
Opin 2013;29:1147–60; 
39. Sihvonen S, Korpela M, Mustonen J, et al. Mortality in patients with rheumatoid 
arthritis treated with low-dose oral glucocorticoids. A population-based cohort 
study. J Rheumatol 2006;33:1740–6; 
36 
 
40. del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds 
associated with all-cause and cardiovascular mortality in rheumatoid 
arthritis. Arthritis Rheum 2014;66:264–72; 
41. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact 
of disease activity, treatment with glucocorticoids, TNFα inhibitors and 
rituximab. Ann Rheum Dis 2015;74:415–21; 
42. Ajeganova S, Svensson B, Hafström I, BARFOT Study Group. Low-dose 
prednisolone treatment of early rheumatoid arthritis and late cardiovascular 
outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ 
Open 2014;4:e004259; 
43. de Hair M, IJff N, Jacobs J, et al. Long-term adverse events after daily 
concomitant treatment with 10 mg prednisone in the 2-year computer assisted 
management in early rheumatoid arthritis trial-II [abstract]. Arthritis 
Rheumatol 2015;67(Suppl 10):856–7; 
44. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor 
inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and 
corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and 
psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum 
Dis 2015;74:480–9; 
45. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by 
low-dose corticosteroids in rheumatoid arthritis: a systematic literature 
review. Joint Bone Spine 2011;78:23–30; 
46. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of 
hospitalization for pneumonia: associations with prednisone, disease-modifying 
antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis 
Rheum2006;54:628–34; 
47. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-
modifying antirheumatic drugs and risk of infection in patients with rheumatoid 
arthritis. Arthritis Rheum 2008;59:1074–81; 
48. Haraoui B, Jovaisas A, Bensen WG, et al. Use of corticosteroids in patients with 
rheumatoid arthtritis treated with infliximab: treatment implications based on a 
real-world Canadian population. RMD Open 2015;1;e000078; 
49. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Infections induced by low-dose 
corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone 
Spine 2010;77:246–51; 
37 
 
50. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed 
impact of oral glucocorticoid therapy on risk of serious infection in older patients 
with rheumatoid arthritis: a nested case-control analysis. Ann Rheum 
Dis 2012;71:1128–33; 
51. Deandrade JR, McCormick JN, Hill AG. Small doses of prednisolone in the 
management of rheumatoid arthritis. Ann Rheum Dis 1964;23:158–62; 
52. Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. The timing of 
glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 
1997;56:27–31; 
53. De Silva M, Binder A, Hazleman BL. The timing of prednisolone dosage and its 
effect on morning stiffness in rheumatoid arthritis. Ann Rheum Dis 1984;43:790–
3; 
54. Kolar P, Buttgereit F. EULAR evidence-based recommendations on the 
management of systemic glucocorticoid therapy in rheumatic diseases. Z 
Rheumatol 2009;68:349–52; 
55. Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD 
Open 2016;2:e000203; 
56. Caporali R, Todoerti M, Sakellariou G, Montecucco C. Glucocorticoids in 
rheumatoid arthritis. Drugs 2013;73:31–43; 
57. Buttgereit F, Smolen JS, Coogan AN, Cajochen C. Clocking in: chronobiology in 
rheumatoid arthritis. Nat Rev Rheumatol 2015;11:349–56; 
58. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World 
Health Organ 2003;81:646–56; 
59. Zamora-Legoff JA, Myasoedova E, Matteson EL, Achenbach SJ, Crowson CS. 
Drug prescribing trends in adults with rheumatoid arthritis: a population-based 
comparative study from 2005 to 2014. Clin Rheumatol 2016;35:2427–36; 
60. Zamora-Legoff JA, Achenbach SJ, Crowson CS, Krause ML, Davis JM III, 
Matteson EL. Opioid use in patients with rheumatoid arthritis 2005–2014: a 
population-based comparative study. Clin Rheumatol 2016;35:1137–44; 
61. Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, Abril A, 
Bachta A, Balint P, Barraclough K, Bianconi L, Buttgereit F, Carsons S, Ching 
D, Cid M, Cimmino M, Diamantopoulos A, Docken W, Duftner C, Fashanu B, 
Gilbert K, Hildreth P, Hollywood J, Jayne D, Lima M, Maharaj A, Mallen C, 
Martinez-Taboada V, Maz M, Merry S, Miller J, Mori S, Neill L, Nordborg E, 
Nott J, Padbury H, Pease C, Salvarani C, Schirmer M, Schmidt W, Spiera R, 
38 
 
Tronnier D, Wagner A, Whitlock M, Matteson EL, Dasgupta B. 
Recommendations for the management of polymyalgia rheumatica: a European 
League Against Rheumatism/American College of Rheumatology collaborative 
iniziative. Ann Rheum Dis 2015;74(10):1799-807; 
62. Yildirim-Toruner C, Diamond B: Currentand novel therapeutics in the 
treatmentof systemic lupus erythematosus. J AllergyClin Immunol 2011; 127: 
303-1 
63. Mazzantini M, Talarico R, Doveri Met al.: Incident comorbidity among 
patientswith rheumatoid arthritis treated or not withlow-dose glucocorticoids: a 
retrospectivestudy. J Rheumatol 2010, 37: 2232-6; 
64. Mosca M, Tani C, Carli L, Bombardieri S. Glucocorticoids in systemic lupus 
erythematosus. Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S126-9; 
65. van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Dijkmans BA, Boers M. Why 
are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early 
rheumatoid arthritis? Ann Rheum Dis 2007;66(7):974–76; 
66. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, 
Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Guillevin L, Holland 
M, Kirwan JR, Rovensky J, Saag KG, Severijns G, Webber S, Westhovens R, 
Bijlsma JW. Patient and rheumatologist perspectives on glucocorticoids: an 
exercise to improve the implementation of the European League Against 
Rheumatism (EULAR) recommendations on the management of systemic 
glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69(6):1015–
21; 
67. Da Silva JA, Jacobs JW, Bijlsma JV: Revisiting the toxicity of low- dose 
glucocorticoids: risks and fears. Ann N Y Acad Sci 2006; 1069: 275-88; 
68. Hoes JN, Jacobs JWG, Boers M et al.:EULAR evidence based recommendations 
on the management of systemic glucocorticoid therapy in rheumatic diseases. 
AnnRheum Dis 2007; 66: 1560-7; 
69. Nakamura J, Ohtori S, Sakamoto M, Chuma A, Abe I, Shimizu K: Development 
of new osteonecrosis in systemic lupus erythematosus patients in association with 
longterm corticosteroid therapy after disease recurrence. Clin Exp Rheumatol 
2010; 28:13-8; 
70. Pocock NA, Eisman JA, Dunstan CR, Evans RA, Thomas DH, Huq NL. 
Recovery from steroid-induced osteoporosis. Ann Intern Med 1987;107:319–23;  
39 
 
71. Henneicke H, Herrmann M, Kalak R, Brennan-Speranza TC, Heinevetter 
U, Bertollo N, Day RE, Huscher D, Buttgereit F, Dunstan CR, Seibel MJ, Zhou 
H.Corticosterone selectively targets endo-cortical surfaces by an osteoblast-
dependent mechanism. Bone 2011;49:733-42; 
72. G. Pearce, P. F. J. Ryan, P. D. Delmas, D. A. Tabensky and E. Seeman. The 
deleterious effects of low-dose corticosteroids on bone density in patients with 
polymyalgia rheumatica. British Journal of Rheumatology 1998;37:292–99;  
73. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral 
corticosteroids and risk fractures. J Bone Miner Res 2000;15:993-1000; 
74. Vestergaard P, Olsen ML, Paaske JS et al. Corticosteroid use and risk of hip 
fracture: a population-based case-control study in Denmark. J Intern Med 
2003;254(5):486–93;  
75. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced 
osteoporosis: pathophysiology and therapy. Osteoporos Int. 2013;18:1319-28; 
76. Compston J. Management of Glucocorticoid-induced osteoporosis. Nat Rev 
Rheumatol. 2010;6:82-8; 
77. Xia X, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, et al. 
Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res. 
2010;25:2479–88; 
78. Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte 
viability with glucocorticoid treatment: relation to histomorphometry. Ann 
Rheum Dis. 2003;62:1215–7; 
79. Canalis E. Wnt signaling in osteoporosis: mechanisms and novel therapeutic 
approaches. Nat Rev Endocrinol. 2013;9:575–83; 
80. Pinzone JJ, Hall BM, Thudi NK, Vonau M, et al. The role of Dickkopf-1 in bone 
development, homeostasis, and disease. Blood 2009;113: 517-525; 
81. Rossini M, Gatti D, Adami S. Involvement of WNT/β-catenin signaling in the 
treatment of osteoporosis.Calcif Tissue Int. 2013;93:121-32; 
82. Li X, Zhang Y, Kang H, Liu W, et al. Sclerostin binds to LRP5/6 and antagonizes 
canonical Wnt signaling. J Biol Chem. 2005;280: 19883-7; 
83. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone 
formation in the adult skeleton. Endocrinology 2007;148: 2635-2643; 
84. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids 
and tumor necrosis factor α increase oxidative stress and suppress Wnt protein 
signaling in osteoblasts. J Biol Chem. 2011;52:44326–35;  
40 
 
85. Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoid-
dependent regulation of Wnt expression and its inhibitors in mature osteoblastic 
cells. Calcif Tissue Int. 2009;85:538–45;  
86. Hurson CJ, Butler JS, Keating DT, Murray DW, Sadlier DM, O’Byrne JM, et al. 
Gene expression analysis in human osteoblasts exposed to dexamethasone 
identifies altered developmental pathways as putative drivers of osteoporosis. 
BMC Musculoskelet Disord. 2007;8:12;  
87. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid 
excess in mice results in early activation of osteoclastogenesis and adipogenesis 
and prolonged suppression of osteogenesis: a longitudinal study of gene 
expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 
2008;58:1674–86; 
88. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of dickkopf-1 
attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic 
differentiation, and bone mass loss. Endocrinology 2008;149:1793–801; 
89. Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, et 
al. Selective glucocorticoid receptor modulation maintains bone mineral density 
in mice. J Bone Miner Res. 2012;27:2242–50; 
90. Lenore Buckley, Gordon Guyatt, Howard A. Fink, Michael Cannon, Jennifer 
Grossman, Karen E. Hansen, Mary Beth Humphrey, Nancy E. Lane, Marina 
Magrey, Marc Miller, Lake Morrison, Madhumathi Rao, Angela Byun Robinson, 
Sumona Saha, Susan Wolver, Raveendhara R. Bannuru, Elizaveta Vaysbrot, 
Mikala Osani, Marat Turgunbaev, Amy S. Miller, and Timothy McAlindon.  
2017 American College of Rheumatology Guideline for the Prevention and 
Treatment of Glucocorticoid-Induced Osteoporosis ARTHRITIS & 
RHEUMATOLOGY Vol. 69, No. 8, August 2017, pp 1521–1537;  
91. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and 
frequency of oteoporosis in female patients with rheumatoid arthritis: results 
from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis 
Rheum 2000;43:522–30; 
92. Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno 
O, Frediani B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S.A 
multicenter cross sectional study on bone mineral density in rheumatoid arthritis. 
Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 
2000;27:2582–9; 
41 
 
93. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, 
Ronday HK, Peeters AJ, et al. Bone mineral density in patients with recently 
diagnosed, active rheumatoid arthritis. Ann Rheum Dis 2007;66:1508–12; 
94. LeeTJH, Sung YK, Choi CB, Cho SK, Bang SY, Choe JY, Hong SJ, Jun JB, Kim 
TH, Lee J, Lee HS, Yoo DH, Yoon BY, Bae SC.The frequency of and risk 
factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC 
Musculoskelet Disord 2016;17(1):98; 
95. Gonzalez-Lopez L, Gamez-Nava JI, Vega-Lopez A, Rodriguez-Jimenez NA, 
Gonzalez-Montoya N, Aguilar-Chavez E, et al. Performance of risk indices for 
identifying low bone mineral density and osteoporosis in Mexican Mestizo 
women with rheumatoid arthritis. J Rheumatol 2000;39:247–53; 
96. Heberlein I, Demary W, Bloching H, Braun J, Buttgereit F, Dreher R, et 
al.Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis 
(ORA study). Z Rheumatol 2011;70:793–8; 
97. L Carli, C Tani, V Spera, R Vagelli, S Vagnani,  M Mazzantini, O Di Munno, M 
Mosca. Risk factors for osteoporosis and fragility fractures in patients with 
systemic lupus erythematosus. Lupus Sci Med 2016;3(1):e000098; 
98. Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women 
with systemic lupus erythematosus. Clin Rheumatol 2003;22:318–23; 
99. Uaratanawong S, Deesomchoke U, Lertmaharit S, Uara-tanawong S. Bone 
mineral density in premenopausal women with systemic lupus erythematosus. J 
Rheumatol 2003;30:2365–8; 
100. Zhu TY, Griffith JF, Au SK, Tang XL, Kwok AW, Leung PC, Li 
EK, Tam LS. (2014) Bone mineral density change in systemic lupus 
erythematosus: a 5-year followup study. J Rheumatol; 41:1990-7; 
101. Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans 
BA, Lems WF, Voskuyl AE, Bultink IE.Six year followup study of bone mineral 
density in patients with systemic lupus erythematosus. Osteoporos Int 
2013;24:1287-33; 
102. R. M. R. Pereira, J. F. de Carvalho, and E. Canalis.Glucocorticoid-
induced osteoporosis in rheumatic diseases. Clinics 2010;65(11):1197–1205; 
103. Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli 
M, Oberhollenzer F, Lorenzini R, Redlich K, Axmann R, Zwerina J, Willeit J. 
High-sensitivity C-reactive protein and risk of non traumatic fractures in the 
Bruneck study. Arch Intern Med 2006;166:2495–501; 
42 
 
104. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating 
levels of inflammatory markers predict change in bone mineral density and 
resorption in older adults: a longitudinal study. J Clinical Endocrinol Metab 
2008;93:1952–8; 
105. Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor 
M, Tylavsky FA, Cummings SR, Harris TB, Newman AB; Health ABC 
Study.Inflammatory markers and incident fracture risk in older men and women: 
the Health Aging and Body Composition Study. J Bone Miner Res 
2007;22:1088–95;  
106. Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs 
BL.Effect of blockade of TNF-α and interleukine-1 action on bone resorption in 
early postmenopausal women. J Bone Miner Res 2007;22:724–9; 
107. Zhong Z, Ethen NJ, Williams BO. WNT signaling in bone 
developmentand homeostasis. Wiley Interdiscip Rev Dev Biol 2014; 3: 489–500; 
108. Klein GL, Herndon DN, Le PT et al. The effect of burn on serum 
concentrations of sclerostin and FGF23. Burns 2015; 41: 1532–1535;  La Corte 
R, Trotta F, Adami S. Glucocorticoid receptors and bone. Curr Pharm Des 2010; 
16: 3586–3592;  
109. Ohnaka K, Tanabe M, Kawate H et al. Glucocorticoid suppresses the 
canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res 
Commun 2005; 329: 177–181; 
110. Brabnikova Maresova K, Pavelka K, Stepan JJ. Acute effects of 
glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. 
Calcif Tissue Int 2013; 92: 354–36; 
111. Gifre L, Ruiz-Gaspa S, Monegal A et al. Effect of glucocorticoid 
treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their 
relationship with bone turnover. Bone 2013; 57: 272–276; 
112. Chen XX, Baum W, Dwyer D, Stock M, Schwabe K, Ke HZ, Stolina 
M, Schett G, Bozec A. Sclerostin inhibition reverses systemic, periarticular and 
local bone loss in arthritis. Ann Rheum Dis 2013;72:1732–6; 
113. Belaya ZE, Rozhinskaya LY, Melnichenko GA et al. Serum extracellular 
secreted antagonists of the canonicalWnt/beta-catenin signaling pathway in 
patients with Cushing's syndrome. Osteoporos Int 2013; 24: 2191–2199; 
114. van Lierop AH, van der Eerden AW, Hamdy NA et al. 
Circulatingsclerostin levels are decreased in patients with endogenous 
43 
 
hypercortisolismand increase after treatment. J Clin Endocrinol Metab 2012; 97: 
E1953–E1957; 
115. Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, 
Povino MR, Orsolini G, Gatti D. In patients with rheumatoid arthritis, Dickkopf-
1 serum levels are correlated with parathyroid hormone, bone erosions and bone 
mineral density.Clin Exp Rheumatol. 2015;33:77-83; 
116. Eric E Beier, Tzong-Jen Sheu, Emily A Resseguie, Masahiko Takahata, 
Hani A Awad, Deborah A Cory-Slechta and J Edward Puzas. Sclerostin activity 
plays a key role in the negative effect of glucocorticoid signaling on osteoblast 
function in mice Bone Research (2017) 5, 17013; 
117. Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-
CCP autoantibodies in rheumatoid arthritis.Rheumatology (Oxford) 
2006;45(1):20–25; 
118. Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, Araujo 
E, Hueber AJ, Harre U, Engelke K, Schett G.Bone loss before the clinical onset 
of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann 
Rheum Dis 2014;73(5):854-60; 
119. Rossini M, Bagnato G, Frediani B, Iagnocco A, LA Montagna G, 
Minisola G, Caminiti M, Varenna M, Adami S. Relationship of focal erosions, 
bone mineral density, and parathyroid hormone in rheumatoid arthritis.J 
Rheumatol 2011;38:997-1002; 
120. Rossini M, Adami G, Viapiana O, Idolazzi L, Gatti D.Denosumab, 
cortical bone and bone erosions in rheumatoid arthritis.Ann Rheum Dis 2016;pii: 
annrheumdis-2016-210022. doi: 10.1136/annrheumdis-2016-210022. [Epub 
ahead of print];  
121. van Staa TP, Leufkens HG, Cooper C. The epidemiology of 
corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 
2002;13:777–87;  
122. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III 
LJ, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey 
EV, Mellstrom D. A meta-analysis of prior corticosteroid use and fracture risk. J 
Bone Miner Res 2004;19:893–9;  
123. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini 
S, Giorgino R, Moro L, Giustina A.High prevalence of asymptomatic vertebral 
44 
 
fractures in post-menopausal women receiving chronic glucocorticoid therapy: a 
cross-sectional outpatient study. Bone 2006;39(2):253–9;  
124. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone 
density threshold and other predictors of vertebral fracture in patients receiving 
oral glucocorticoid therapy. Arthritis Rheum 2003;48(11):3224-9;  
125. Lacativa PG, Farias ML.Osteoporosis and Inflammation. Arq Bras 
Endocrinol Metabol 2010;54(2):123-32; 
126. Fessel KD, Nevitt MC.Correlates of fear of falling and activity limitation 
among persons with rheumatoid arthritis. Arthritis Care Res 1997;10:222–8; 
127. Kaz Kaz H, Johnson D, Kerry S, Chinappen U, Tweed K, Patel S.Fall-
related risk factors and osteoporosis in women with rheumatoid arthritis. 
Rheumatology (Oxford) 2004;43(10):1267-71; 
128. Bearne LM, Scott DL, Hurley MV.Exercise can reverse quadriceps 
sensimotor dysfunction that is associated with rheumatoid arthritis without 
exacerbating disease activity. Rheumatology 2002;41:157-66; 
129. Rossini M, Gatti D, Viapiana O, Caimmi C, Idolazzi L, Fracassi E, 
Adami S. Vitamin D and rheumatic diseases.Reumatismo 2014;66:153-70; 
130. Rossini M, D'Avola G, Muratore M, Malavolta N, Silveri F, Bianchi G, 
Frediani B, Minisola G, Sorgi ML, Varenna M, Foti R, Tartarelli G, Orsolini G, 
Adami S; Study Group on Osteoporosis and Metabolic Skeletal Diseases of the 
Italian Society of Rheumatology (SIR). Regional differences of vitamin D 
deficiency in rheumatoid arthritis patients in Italy.Reumatismo 2013;65:113-20; 
131. Rossini M, Maddali Bongi S, La Montagna G, Minisola G, Malavolta N, 
Bernini L, Cacace E, Sinigaglia L, Di Munno O, Adami S. Vitamin D deficiency 
in rheumatoid arthritis: prevalence, determinants and associations with disease 
activity and disability.Arthritis Res Ther 2010;12:R216; 
132. Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti 
A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, 
Isaia GC. Guidelines for the diagnosis, prevention and management of 
osteoporosis.Reumatismo 2016;68:1-39; 
133. Rossini M, Orsolini G, Viapiana O, Adami S, Gatti D.Bisphosphonates in 
the treatment of glucocorticoid-induced osteoporosis: pros.Endocrine 
2015;49:620-7; 
134. Saag KG, Zanchetta JR, de Vogelaer JP et al., Effects of teriparatide 
versus alendronate for testing glucocorticoid-inducedosteoporosis: 36 months 
45 
 
results of a randomized, double-blind controlled trial. Arthritis Rheum 
2009;60:3346–55; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
Table 1: Features of Patients depending on the Rheumatic Disease (Mean ± SD) 
Rheumatic 
Diseases 
N. F/M AGE 
(yrs) 
BMI 
(Kg/m2) 
CUMULATIVE 
DOSE (g) 
LENGTH 
OF 
THERAPY 
(mo) 
AR 183 157/26 64±13* 25±5 20,3±22,9 108±91 
CTDs 249 206/43 57±16* 25±4 23,9±42,9 79±84* 
PMR 91 71/20 74±6* 26±5* 6,3±10,1* 29±53* 
*p<0,05 between groups 
 
 
 
 
 
Table 2: Prevalence of risk factors for osteoporosis or fracture, according to the 
Rheumatic Disease 
RISK FACTORS RA CTDs PMR 
FAMILY HISTORY OF FRACTURE 15% 23% 13% 
ALCOOL HABITS 20% 19% 34% 
SMOKING HABITS 
(CURRENTLY/PREVIOUS) 
19%/23% 19%/17% 9%/26% 
FALLS DURING LAST 6 MONTHS 20% 15% 19% 
NO PHYSICAL ACTIVITY 42% 42% 39% 
SUNLIGHT EXPOSURE<1/WEEK 37% 35% 18% 
NO SEA HOLIDAY 66% 63% 60% 
LOW CALCIUM INTAKE 30% 23% 34% 
COMORBIDITIES 78% 76% 98% 
VAS-EQ-5D<50%* 23% 18% 20% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Visual analogue scale for recording European Quality of Life-5 Dimensions 
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Legend of the Figures 
 
Fig.1: Enrolling centers 
Fig.2: Inclusion/Exclusion citeria flow-chart 
Fig.3,4,5,6,7: CRF used to collect information about the medical history, clinical, diagnostic and 
therapeutic data, and in particular: demographics; physiological and pathological history; 
assessment of the state of the rheumatic disease and concomitant Health Assessment 
Questionnaire; previous drug therapy; previous and ongoing glucocorticoid therapy; specific 
anamnesis for osteoporosis: date of first diagnosis; date of  first atraumatic fracture; pain 
symptoms; previous fractures (before or after the start of therapy GC)/fractures at the baseline 
visit; outcome laboratory examinations; previous/ongoing drug therapy for osteoporosis; risk 
factors;assessment of the quality of life (EQ-5D); simplified questionnaire of calcium and vitamin 
D intake and physical activity 
Fig. 8: Prevalence of osteoporosis at spine or femoral neck depending on the Rheumatic Disease   
Fig.9: A) Prevalence of patients with fractures pre-GC treatment, according to the Rheumatic 
Diseases B) Prevalence of patients with new clinical fragility fractures in the different Rheumatic 
Diseases during GC treatment 
Fig.10: A)Distribution of different types of fractures, in the different diseases, during GC treatment 
B) Prevalence of RA or CTDs patients with recurrence of fractures during GC treatment 
Fig.11: A) Prevalence of patients with calcium and/or vitamin D supplementation, before or during 
GC treatment, according to the Rheumatic Disease B) Prevalence of patients on prevention or 
treatment of osteoporosis with specific drugs, depending on the Rheumatic Disease. 
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